Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05131022 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 2 of 62 sitesv35
  2. Site details revised at 2 of 62 sitesv34
  3. Site details revised at 1 of 62 sitesv33
  4. Site details revised at 1 of 62 sitesv32
  5. Site details revised at 1 of 62 sitesv31
Show 29 earlier versionsHide 29 earlier versions
  1. Study sites: 61 to 62v30
  2. Site details revised at 1 of 61 sitesv29
  3. Study sites: 57 to 61v28
  4. Enrollment target: 492 to 572 Study sites: 47 to 57 · Eligibility criteria expanded, about 16 words · Study arms: 15 to 19 · 1 morev27 Show 4 more changesShow less
    • Study sites: 47 to 57
    • Eligibility criteria expanded, about 16 words
    • Study arms: 15 to 19
    • Study description expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites: 35 to 47v26
  6. Enrollment target: 292 to 492 Primary completion date: Dec 2025 to Jan 2027 · Primary endpoints: 4 to 5 · Study sites: 25 to 35 · 5 morev25 Show 8 more changesShow less
    • Primary completion date: Dec 2025 to Jan 2027
    • Primary endpoints: 4 to 5
    • Study sites: 25 to 35
    • Completion date: Jan 2027 to Jan 2028
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: 6 to 7
    • Study description expanded, about 64 words
    • Study arms: 8 to 15

    See this version in full on ClinicalTrials.gov ↗

  7. Study sites: 24 to 25v24
  8. Site details revised at 1 of 24 sitesv23
  9. Re-verified, no change to tracked fieldsv22
  10. Study sites: 23 to 24v21
  11. Enrollment target: 226 to 292 Study sites: 20 to 23 · Study description expanded, about 23 wordsv20 Show 2 more changesShow less
    • Study sites: 20 to 23
    • Study description expanded, about 23 words

    See this version in full on ClinicalTrials.gov ↗

  12. Study sites: 18 to 20v19
  13. Enrollment target: 130 to 226 Primary endpoints revised (4) · Eligibility criteria expanded, about 54 words · Study description shortened, about 57 words · 1 morev18 Show 4 more changesShow less
    • Primary endpoints revised (4)
    • Eligibility criteria expanded, about 54 words
    • Study description shortened, about 57 words
    • Study arms: 5 to 8

    See this version in full on ClinicalTrials.gov ↗

  14. Study sites: 15 to 18v17
  15. Study sites: 14 to 15v16
  16. Primary completion date: Jan 2024 to Dec 2025 Study sites: 11 to 14 · Completion date: May 2024 to Jan 2027 · Secondary endpoints: details revised at 6 of 6 entriesv15 Show 3 more changesShow less
    • Study sites: 11 to 14
    • Completion date: May 2024 to Jan 2027
    • Secondary endpoints: details revised at 6 of 6 entries
  17. Re-verified, no change to tracked fieldsv14
  18. Study sites: 10 to 11v13
  19. Study sites: 9 to 10v12
  20. Study sites: 8 to 9v11
  21. Eligibility criteria shortened, about 35 words Study description shortened, about 231 words · Site contacts updated at 1 of 8 sitesv10 Show 2 more changesShow less
    • Study description shortened, about 231 words
    • Site contacts updated at 1 of 8 sites

    See this version in full on ClinicalTrials.gov ↗

  22. Study sites: 7 to 8v9
  23. Study sites: 6 to 7 Eligibility criteria shortened, about 7 words · Study description expanded, about 145 words · Study arms: 6 to 5v8 Show 3 more changesShow less
    • Eligibility criteria shortened, about 7 words
    • Study description expanded, about 145 words
    • Study arms: 6 to 5

    See this version in full on ClinicalTrials.gov ↗

  24. Study sites: 4 to 6v7
  25. Study sites: 3 to 4v6
  26. Study sites: 2 to 3v5
  27. Eligibility criteria expanded, about 66 words Study description expanded, about 89 wordsv4 Show 1 more changeShow less
    • Study description expanded, about 89 words

    See this version in full on ClinicalTrials.gov ↗

  28. Study sites: 1 to 2 Start date changed from estimate of Mar 2022 to Apr 13, 2022 · Study title expanded, about 1 wordv3 Show 2 more changesShow less
    • Start date changed from estimate of Mar 2022 to Apr 13, 2022
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  29. Trial status: Not Yet Recruiting to Recruiting Start date: Nov 2021 to Mar 2022 · Study sites: 0 to 1 · Eligibility criteria shortened, about 4 words · 1 morev2 Show 4 more changesShow less
    • Start date: Nov 2021 to Mar 2022
    • Study sites: 0 to 1
    • Eligibility criteria shortened, about 4 words
    • Study title shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Nurix Therapeutics, Inc.
7 trials monitored
See 1 trial at risk
Leukemia
2,566 trials monitored
See 143 trials at risk
Non-Hodgkin Lymphoma
1,517 trials monitored
See 84 trials at risk
DLBCL
650 trials monitored
See 38 trials at risk
and 3 more diseases
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients with advanced B-cell malignancies.
Trial Details
NCT Number NCT05131022
Lead Sponsor Nurix Therapeutics, Inc.
Conditions Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Waldenstrom Macroglobulinemia (WM), Primary Central Nervous System Lymphoma (PCNSL) +1 more
Enrollment 572 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov